The company said, "The financial terms of the agreement were not disclosed. Kite will acquire all outstanding shares of Tmunity other than those already owned by Kite. Beginning in the first quarter of 2022, consistent with guidance from the U.S. Securities and Exchange Commission (SEC), Gilead no longer excludes acquired IPR&D expenses from its non-GAAP financial measures and expects the transaction with Tmunity to reduce Gilead’s GAAP and non-GAAP 2023 EPS by approximately $0.18-$0.22."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GILD:
- Gilead, Arcus announce results from fourth interim analysis of ARC-7 study
- GILD vs. AMGN: Two Splendid Dividend Stocks, but One Looks Better
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Gilead resumed with a Neutral at BofA
- Kite announces three-year follow-up data from Yescarta therapy